Taysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 26,918 Shares

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 26,918 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $124,091.98. Following the completion of the transaction, the insider owned 1,317,389 shares of the company’s stock, valued at $6,073,163.29. This trade represents a 2.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Sukumar Nagendran also recently made the following trade(s):

• On Friday, January 23rd, Sukumar Nagendran sold 89,132 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total value of $423,377.00.
• On Monday, January 12th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00.
• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total value of $523,093.75.
• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97.

Taysha Gene Therapies Stock Up 0.8%

TSHA traded up $0.04 during trading hours on Tuesday, hitting $4.76. 1,384,585 shares of the company’s stock were exchanged, compared to its average volume of 2,812,476. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $6.02. The stock’s 50-day moving average is $5.08 and its two-hundred day moving average is $4.07. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -14.42 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on TSHA shares. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Needham & Company LLC reissued a “buy” rating and set a $10.00 price target on shares of Taysha Gene Therapies in a research note on Friday, October 17th. Wells Fargo & Company boosted their price target on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Chardan Capital reissued a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Finally, Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Institutional Trading of Taysha Gene Therapies

Hedge funds have recently made changes to their positions in the company. Jefferies Financial Group Inc. grew its stake in Taysha Gene Therapies by 4,105.3% in the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after buying an additional 10,068,479 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at $11,178,000. Barclays PLC grew its position in Taysha Gene Therapies by 1,042.8% during the 3rd quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock worth $16,834,000 after acquiring an additional 4,697,611 shares during the last quarter. MPM Bioimpact LLC bought a new position in shares of Taysha Gene Therapies during the second quarter valued at about $6,823,000. Finally, Vestal Point Capital LP increased its position in Taysha Gene Therapies by 83.3% during the 3rd quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock valued at $17,985,000 after purchasing an additional 2,500,000 shares during the period. 77.70% of the stock is currently owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.